Relugolix

An orally active, nonpeptide GnRH receptor antagonist used to treat advanced prostate cancer and, in combination with estradiol and norethindrone acetate, moderate to severe symptoms associated with uterine fibroids and endometriosis. Relugolix competitively blocks pituitary GnRH receptors, rapidly reducing LH and FSH secretion and consequently suppressing testosterone or ovarian estrogen production. Unlike GnRH receptor agonists, it does not cause an initial gonadotropin or testosterone surge. Important adverse effects include hot flashes, reduced bone mineral density, and other consequences of sex hormone suppression

CAS Number: 737789-87-6

Molecular Mass: 623.6 g/mol

Formula: C₂₉H₂₇F₂N₇O₅S

Smiles: CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1

Synonymes:

Relugolix, 737789-87-6, TAK-385, Orgovyx, TAK 385, TAK385, P76B05O5V6, DTXSID40224167, MYFEMBREE COMPONENT RELUGOLIX, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, N-[4-[1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-N'-methoxyurea, 1-(4-{1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1H,2H,3H,4H-thieno[2,3-d]pyrimidin-6-yl}phenyl)-3-methoxyurea, Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy-, relugolixum, 1-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1H,2H,3H,4H-thieno(2,3-d)pyrimidin-6-yl)phenyl)-3-methoxyurea, 1-(4-(1-((2,6-difluorophenyl)methyl)-5-(dimethylaminomethyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno(4,5-e)pyrimidin-6-yl)phenyl)-3-methoxyurea, 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-(dimethylaminomethyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[4,5-e]pyrimidin-6-yl]phenyl]-3-methoxyurea, Urea, N-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-N'-methoxy-, RefChem:57784, DTXCID40146658, 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea, C29H27F2N7O5S, CHEMBL1800159, 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea, Relugolix [USAN:INN], UNII-P76B05O5V6, Orgovyx (TN), MFCD25976856, Relugolix (Standard), RELUGOLIX [INN], RELUGOLIX [JAN], Relugolix(TAK-385), RELUGOLIX [USAN], Relugolix(TAK-385)?, RELUGOLIX [WHO-DD], Relugolix (JAN/USAN/INN), SCHEMBL778416, GTPL5586, orb1303979, orb3141153, RELUGOLIX [ORANGE BOOK], SCHEMBL29386968, AOMXMOCNKJTRQP-UHFFFAOYSA-N, GLXC-10592, HMS5085J09, EX-A1083, TAK-385, RVT-601, BDBM50347982, EBC-17169, HY-16474R, s5808, AKOS027440398, CS-5917, DB11853, SB16721, AC-35863, BP-44043, BS-18032, HY-16474, NS00072569, D10888, EN300-19854622, F979301, Ryeqo (relugolix-estradiol-norethisterone acetate), Q21099000, 1-(4-{1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}phenyl)-3-methoxyurea, 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-thieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxy-urea, 1-{4-[1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea, N-(4-{1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}phenyl)-N'-methoxyurea, N-[4-[1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-N'-methoxyurea, 1-[4-[1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea, Orgovyx, RVT 601, TAK 385

Bioactivity: Selective, competitive gonadotropin-releasing hormone (GnRH) receptor antagonist; suppressor of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion

Solubility in Different Solvents

Solvent	Temperature [K]	Crystal form	Solubility [mg/mL]	Reference
Acetonitrile	298.15	-	5.702	[152]
Acetonitrile	303.15	-	6.858	[152]
Acetonitrile	308.15	-	7.765	[152]
Acetonitrile	313.15	-	8.693	[152]
Acetonitrile	318.15	-	9.822	[152]
Acetonitrile	323.15	-	11.38	[152]
Ethanol	298.15	-	1.425	[152]
Ethanol	303.15	-	1.607	[152]
Ethanol	308.15	-	1.797	[152]
Ethanol	313.15	-	2.185	[152]
Ethanol	318.15	-	2.6	[152]
Ethanol	323.15	-	3.111	[152]
Ethyl acetate	298.15	-	2.331	[152]
Ethyl acetate	303.15	-	2.5	[152]
Ethyl acetate	308.15	-	2.81	[152]
Ethyl acetate	313.15	-	3.132	[152]
Ethyl acetate	318.15	-	3.319	[152]
Ethyl acetate	323.15	-	3.522	[152]
Isopropanol	298.15	-	0.535	[152]
Isopropanol	303.15	-	0.669	[152]
Isopropanol	308.15	-	0.826	[152]
Isopropanol	313.15	-	0.9965	[152]
Isopropanol	318.15	-	1.213	[152]
Isopropanol	323.15	-	1.505	[152]
Methanol	298.15	-	6.706	[152]
Methanol	303.15	-	7.762	[152]
Methanol	308.15	-	8.745	[152]
Methanol	313.15	-	9.609	[152]
Methanol	318.15	-	10.66	[152]
Methanol	323.15	-	11.5	[152]

Molecule 3D descriptors

Descriptor	Value
PMI1	4434.3745
PMI2	16539.2931
PMI3	19617.9224
NPR1	0.2260
NPR2	0.8431
RadiusOfGyration	5.7047
InertialShapeFactor	0.0002
Eccentricity	0.9741
Asphericity	0.4692
SpherocityIndex	0.1323
PBF	1.0628